Clinical Trial

Pembrolizumab Plus Olaparib in LA-HNSCC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are drugs that are approved for head and neck cancer treatment. However, FDA has not approved the use of these two drugs together in treating head and neck cancer.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2022-05-04; most recent amendment 2026-01-26.
Status change: Recruiting → Active, Not Recruiting 2026-01-26
Status change: Not Yet Recruiting → Recruiting 2022-09-29
Trial Details
NCT Number NCT05366166
Lead Sponsor UNC Lineberger Comprehensive Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Squamous Cell Carcinoma of Head and Neck
Enrollment 45 participants
Start Date 2022-09-02
Primary Completion 2027-01-21 (estimated)
Study Completion 2030-11-21 (estimated)
Updated on ClinicalTrials.gov 2026-01-28